Lipids & metabolic liver disease

Association between the triglyceride-glucose-frailty index and all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: the mediating role of the poverty-income ratio

Cardiovasc DiabetolPublished Retrospective cohort study

Authors' conclusion

TyGFI levels in individuals with CKM syndrome are nonlinearly associated with increased all-cause and cardiovascular mortality risk. Additionally, the PIR may partially mediate the TyGFI-mortality relationship, highlighting the possible role of socioeconomic factors.

Study context

Population
Participants with cardiovascular-kidney-metabolic (CKM) syndrome, NHANES 2005–2018; mortality via National Death Index to December 31, 2019
Participants
15,044 participants
Exposure
Highest vs lowest triglyceride-glucose-frailty index (TyGFI) tertile
Outcome
All-cause and CV mortality
Follow-up
Median observation 82 months (IQR: 46-123 months)
Methodological detailsNHANES 2005-2018, mediation analysis
  • NHANES 2005-2018
  • Mediation analysis

Main finding

As reported in the abstract

Comprehensive adjustment
Each group vs lowest TyGFI tertileEstimate (95% CI)P value
Highest TyGFI tertile
HR (all-cause mortality) 3.14(2.57–3.83)
P < 0.001
Highest TyGFI tertile
HR (CV mortality) 3.14(2.18–4.52)
P < 0.001
Deaths from all causes
1,103
CV deaths
353

Observational data: associations, not effects.

Further findings

TyGFI continuous, per 1-unit increase

Increase in all-cause mortality risk
56%
Increase in CV mortality risk
52%

Mediation by poverty-income ratio (PIR)

Proportion mediated, all-cause mortality
7.66%
Proportion mediated, CV mortality
8.48%
  • Partial mediation

Subgroups

Consistent associations across demographic strata; significant interaction for marital status

Original publication

Association between the triglyceride-glucose-frailty index and all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: the mediating role of the poverty-income ratio. Cardiovasc Diabetol. Published 25 January 2026. doi:10.1186/s12933-026-03076-5

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.